Therapeutic potential of ADSC-EV-derived lncRNA DLEU2 : A novel molecular pathway in alleviating sepsis-induced lung injury via the miR-106a-5p/LXN axis
Copyright © 2024 Elsevier B.V. All rights reserved..
This study investigates the molecular mechanisms by which extracellular vesicles (EVs) derived from adipose-derived mesenchymal stem cells (ADSCs) promote M2 polarization of macrophages and thus reduce lung injury caused by sepsis. High-throughput sequencing was used to identify differentially expressed genes related to long non-coding RNA (lncRNA) in ADSC-derived EVs (ADSC-EVs) in sepsis lung tissue. Weighted gene co-expression network analysis (WGCNA) was employed to predict the downstream target genes of the lncRNA DLEU2. The RNAInter database predicted miRNAs that interact with DLEU2 and LXN. Functional and pathway enrichment analyses were performed using GO and KEGG analysis. A mouse model of sepsis was established, and treatment with a placebo or ADSC-EVs was administered, followed by RT-qPCR analysis. ADSC-EVs were isolated and identified. In vitro cell experiments were conducted using the mouse lung epithelial cell line MLE-12, mouse macrophage cell line RAW264.7, and mouse lung epithelial cell line (LEPC). ADSC-EVs were co-cultured with RAW264.7 and MLE-12/LEPC cells to study the regulatory mechanism of the lncRNA DLEU2. Cell viability, proliferation, and apoptosis of lung injury cells were assessed using CCK-8, EdU, and flow cytometry. ELISA was used to measure the levels of inflammatory cytokines in the sepsis mouse model, flow cytometry was performed to determine the number of M1 and M2 macrophages, lung tissue pathology was evaluated by H&E staining, and immunohistochemistry was conducted to examine the expression of proliferation- and apoptosis-related proteins. High-throughput sequencing and bioinformatics analysis revealed enrichment of the lncRNA DLEU2 in ADSC-EVs in sepsis lung tissue. Animal and in vitro cell experiments showed increased expression of the lncRNA DLEU2 in sepsis lung tissue after treatment with ADSC-EVs. Furthermore, ADSC-EVs were found to transfer the lncRNA DLEU2 to macrophages, promoting M2 polarization, reducing inflammation response in lung injury cells, and enhancing their viability, proliferation, and apoptosis inhibition. Further functional experiments indicated that lncRNA DLEU2 promotes M2 polarization of macrophages by regulating miR-106a-5p/LXN, thereby enhancing the viability and proliferation of lung injury cells and inhibiting apoptosis. Overexpression of miR-106a-5p could reverse the biological effects of ADSC-EVs-DLEU2 on MLE-12 and LEPC in vitro cell models. Lastly, in vivo animal experiments confirmed that ADSC-EVs-DLEU2 promotes high expression of LXN by inhibiting the expression of miR-106a-5p, further facilitating M2 macrophage polarization and reducing lung edema, thus alleviating sepsis-induced lung injury. lncRNA DLEU2 in ADSC-EVs may promote M2 polarization of macrophages and enhance the viability and proliferation of lung injury cells while inhibiting inflammation and apoptosis reactions, thus ameliorating sepsis-induced lung injury in a mechanism involving the regulation of the miR-106a-5p/LXN axis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
---|---|
Enthalten in: |
International immunopharmacology - 130(2024) vom: 30. März, Seite 111519 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
He, Wei [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.intimp.2024.111519 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369324080 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369324080 | ||
003 | DE-627 | ||
005 | 20240329000658.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240306s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.intimp.2024.111519 |2 doi | |
028 | 5 | 2 | |a pubmed24n1353.xml |
035 | |a (DE-627)NLM369324080 | ||
035 | |a (NLM)38442573 | ||
035 | |a (PII)S1567-5769(24)00037-7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a He, Wei |e verfasserin |4 aut | |
245 | 1 | 0 | |a Therapeutic potential of ADSC-EV-derived lncRNA DLEU2 |b A novel molecular pathway in alleviating sepsis-induced lung injury via the miR-106a-5p/LXN axis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 27.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a This study investigates the molecular mechanisms by which extracellular vesicles (EVs) derived from adipose-derived mesenchymal stem cells (ADSCs) promote M2 polarization of macrophages and thus reduce lung injury caused by sepsis. High-throughput sequencing was used to identify differentially expressed genes related to long non-coding RNA (lncRNA) in ADSC-derived EVs (ADSC-EVs) in sepsis lung tissue. Weighted gene co-expression network analysis (WGCNA) was employed to predict the downstream target genes of the lncRNA DLEU2. The RNAInter database predicted miRNAs that interact with DLEU2 and LXN. Functional and pathway enrichment analyses were performed using GO and KEGG analysis. A mouse model of sepsis was established, and treatment with a placebo or ADSC-EVs was administered, followed by RT-qPCR analysis. ADSC-EVs were isolated and identified. In vitro cell experiments were conducted using the mouse lung epithelial cell line MLE-12, mouse macrophage cell line RAW264.7, and mouse lung epithelial cell line (LEPC). ADSC-EVs were co-cultured with RAW264.7 and MLE-12/LEPC cells to study the regulatory mechanism of the lncRNA DLEU2. Cell viability, proliferation, and apoptosis of lung injury cells were assessed using CCK-8, EdU, and flow cytometry. ELISA was used to measure the levels of inflammatory cytokines in the sepsis mouse model, flow cytometry was performed to determine the number of M1 and M2 macrophages, lung tissue pathology was evaluated by H&E staining, and immunohistochemistry was conducted to examine the expression of proliferation- and apoptosis-related proteins. High-throughput sequencing and bioinformatics analysis revealed enrichment of the lncRNA DLEU2 in ADSC-EVs in sepsis lung tissue. Animal and in vitro cell experiments showed increased expression of the lncRNA DLEU2 in sepsis lung tissue after treatment with ADSC-EVs. Furthermore, ADSC-EVs were found to transfer the lncRNA DLEU2 to macrophages, promoting M2 polarization, reducing inflammation response in lung injury cells, and enhancing their viability, proliferation, and apoptosis inhibition. Further functional experiments indicated that lncRNA DLEU2 promotes M2 polarization of macrophages by regulating miR-106a-5p/LXN, thereby enhancing the viability and proliferation of lung injury cells and inhibiting apoptosis. Overexpression of miR-106a-5p could reverse the biological effects of ADSC-EVs-DLEU2 on MLE-12 and LEPC in vitro cell models. Lastly, in vivo animal experiments confirmed that ADSC-EVs-DLEU2 promotes high expression of LXN by inhibiting the expression of miR-106a-5p, further facilitating M2 macrophage polarization and reducing lung edema, thus alleviating sepsis-induced lung injury. lncRNA DLEU2 in ADSC-EVs may promote M2 polarization of macrophages and enhance the viability and proliferation of lung injury cells while inhibiting inflammation and apoptosis reactions, thus ameliorating sepsis-induced lung injury in a mechanism involving the regulation of the miR-106a-5p/LXN axis | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Adipose-derived mesenchymal stem cells | |
650 | 4 | |a Exosomes | |
650 | 4 | |a LXN | |
650 | 4 | |a Lung injury | |
650 | 4 | |a M2 macrophages | |
650 | 4 | |a Sepsis | |
650 | 4 | |a lncRNA DLEU2 | |
650 | 4 | |a miR-106a-5p | |
650 | 7 | |a MicroRNAs |2 NLM | |
650 | 7 | |a RNA, Long Noncoding |2 NLM | |
650 | 7 | |a DLEU2 lncRNA, human |2 NLM | |
650 | 7 | |a Mirn106 microRNA, mouse |2 NLM | |
650 | 7 | |a latexin protein, mouse |2 NLM | |
650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
700 | 1 | |a Xu, Chengcheng |e verfasserin |4 aut | |
700 | 1 | |a Huang, Yuying |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Qiuzhen |e verfasserin |4 aut | |
700 | 1 | |a Chen, Wang |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Chengkuan |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yun |e verfasserin |4 aut | |
700 | 1 | |a Zheng, Danling |e verfasserin |4 aut | |
700 | 1 | |a XinyueLin |e verfasserin |4 aut | |
700 | 1 | |a Luo, Qianhua |e verfasserin |4 aut | |
700 | 1 | |a Chen, Xiaoshan |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zhihan |e verfasserin |4 aut | |
700 | 1 | |a Wu, Xiaolong |e verfasserin |4 aut | |
700 | 1 | |a Huang, Jianxiang |e verfasserin |4 aut | |
700 | 1 | |a Lin, Chaoxian |e verfasserin |4 aut | |
700 | 1 | |a Huang, Yihui |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Shuyao |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 130(2024) vom: 30. März, Seite 111519 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
773 | 1 | 8 | |g volume:130 |g year:2024 |g day:30 |g month:03 |g pages:111519 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2024.111519 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 130 |j 2024 |b 30 |c 03 |h 111519 |